drugset / Trial / NCT00070941
SAM-e for the Treatment of Depression in Patients With Parkinson's Disease
Phase 2/3
Completed
29 enrolled
NYU Langone Health
National Center for Complementary and Integrative Health (NCCIH) · collabOffice of Dietary Supplements (ODS) · collab
RandomizedFactorialTriple-blindTreatment
Summary
This study will test a chemical called s-adenosyl-methionine (SAM-e) for the treatment of depression in patients with Parkinson's disease (PD).
Timeline
- Start
- 2003-07
- Primary completion
- 2010-06
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Escitalopram | Small molecule | 20 mg | Oral |
| Comparator | Escitalopram | Small molecule | 30 mg | Oral |
| Comparator | Escitalopram | Small molecule | 40 mg | Oral |
| Subject | s-adenosyl-methionine | Unknown | 1200 mg | Oral |
| Subject | s-adenosyl-methionine | Unknown | 1800 mg | Oral |